Nordic Pharma Group

Nordic Group BV has started to commercialize the Anti-Cancer Drug Teysuno® in Europe.

Alizée — 2012-03-21T10:54:46Z

Nordic Group BV (Head office : Hoofddorp, the Netherlands ; CEO and Managing Director : Drs. Hans Schram) has just started marketing Teysuno^(r) an oral fluoropyrimide recently approved in Europe in Advanced gastric cancer .

The product which has been developed by Taiho Pharmaceutical Co., Ltd. (Head office : Tokyo, Japan ; President : Toru Usami) and licensed to the Nordic Group for Europe and other selected Countries is now available in Sweden, Denmark, Norway and Finland and will be progressively introduced in the other European union countries before the end of the year.

Teysuno^(r), a novel oral anti-cancer agent which has received a Marketing Authorization from the EMA for the treatment of adults with Advanced Gastric Cancer when given in combination with cisplatin (March 14, 2011), is available for the first time in this region.

About Teysuno(r) :

A member of the fluoropyrimidine class of anticancer agents, Teysuno(r) is a combination of three pharmacological compounds. The main active substance in Teysuno(r), tegafur, is a prodrug of a chemical called 5-fluorouracil (5-FU), meaning that it is converted in the body to 5-FU. In the body, 5-FU interferes with the enzymes involved in making DNA. As a result, it can prevent the growth of cancer cells or result in cell death.^{^[i]}

The two other active substances in Teysuno(r) allow tegafur to be effective at lower doses and with fewer side effects. Specifically, gimeracil prevents the breakdown of 5-FU and oteracil reduces the activity of 5-FU in normal, non-cancerous tissue in the gut.

Teysuno(r) was authorised for the treatment of gastric cancer in Japan in 1999. Teysuno(r) is also authorized for patients with gastric cancer in South Korea, China, Singapore and Taiwan. To date, Teysuno(r) has been used by more than 870,000 patients in Japan and Asia.
Teysuno(r) has recently obtained its European Marketing Authorization based on the results of FLAGS trial, which has been performed in Western countries.

About Taiho Pharmaceutical

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge : “We strive to improve human health and contribute to the enrichment of society.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in and around the world for developing evidence-based medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people’s efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit www.taiho.co.jp/english/

About Otsuka Holdings Co., Ltd.

The Otsuka Group is a diversified healthcare group operating globally under the corporate philosophy ‘‘Otsuka-people creating new products for better health worldwide’’. The Otsuka Group has business operations in 23 countries and regions around the world, and its consolidated sales for fiscal 2010 is ¥1,090.2 billion.

For more information, please visit the company’s website at www.otsuka.com/en/.

About Nordic Group BV

The Nordic Group is a privately owned, fast growing, fully integrated, pan-European Pharmaceutical company, with a strong focus on the development and commercialization of niche hospital and orphan products and services that cater to the specific needs of clients and patients. In addition to its sales and marketing companies in 13 European countries, operating under the name of Nordic Pharma and Nordic Drugs, the Nordic Group operates as well a number of specialized Pharmaceutical Services companies, specialized in product development, manufacturing, supply logistics, clinical studies and regulatory activities. These companies are operating under the name of Prague Clinical Services, QPharma, Disphar and Indeus. Since its creation, Nordic has enjoyed an average growth of 20% in revenues, and it pursues its expansion through organic growth and strategic collaborations. Additional information can be obtained by visiting Nordic Group’s website at www.nordicpharmagroup.com.

[i] EPAR Summary for the Public : Teysuno (draft). EMA/467/2011, EMEA/H/C/001242. London, : European Medicines Agency, January 2011.

Teysuno™

Alizée — 2011-07-21T15:00:18Z

Taiho Pharmaceutical Co., Ltd and Nordic Group BV Enter into a Development and Commercialization Agreement for the recently EMA approved Anti-Cancer Drug TeysunoTM covering the EU and other Selected European Countries.

Taiho Pharmaceutical Co., Ltd. (Head office : Tokyo, Japan ; President : Toru Usami) and Nordic Group BV (Head office : Hoofddorp, the Netherlands ; CEO and Managing Director : Drs. Hans Schram) have entered into an agreement to support the ongoing development and commercialization of TeysunoTM in the EU and other selected European countries. TeysunoTM, a novel oral anti-cancer agent, recently received Marketing Authorization from the EMA for the treatment of adults with advanced gastric cancer when given in combination with cisplatin (March 14, 2011), which will form the basis of its commercial entry into this region.

Under this agreement Nordic will acquire an exclusive right to commercialize TeysunoTM in their territory and will become the Marketing Authorization Holder.

Nordic will combine its strong track record of success for entering new specialty pharmaceutical markets with its commitment to immediately develop a leading oncology business unit in Europe to ensure doctors and patients throughout the region will soon benefit from their access to TeysunoTM, an important new addition to the treatment of advanced gastric cancer.

The agreement has been structured to encourage and support a strong collaborative environment between the companies from which Taiho's extensive experience with Teysuno in Japan and other countries in Asia will be immediately and seamlessly available to the partnership. About Teysuno

Teysuno™ was authorised for the treatment of gastric cancer in Japan in 1999. Teysuno™ is also authorized for patients with gastric cancer in South Korea, China, Singapore and Taiwan. To date, Teysuno™ has been used by more than 870,000 patients in Japan and Asia.

A member of the fluoropyrimidine class of anticancer agents, Teysuno™ is a combination of three pharmacological compounds. The main active substance in Teysuno, tegafur, is a prodrug of a chemical called 5-fluorouracil (5-FU), meaning that it is converted in the body to 5-FU. In the body, 5-FU interferes with the enzymes involved in making DNA. As a result, it can prevent the growth of cancer cells or result in cell death. The two other active substances in Teysuno™ allow tegafur to be effective at lower doses and with fewer side effects. Specifically, gimeracil prevents the breakdown of 5-FU and oteracil reduces the activity of 5-FU in normal, non-cancerous tissue in the gut.

About Taiho Pharmaceutical

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge : “We strive to improve human health and contribute to the enrichment of society.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing evidence-based medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit www.taiho.co.jp/english/

About Otsuka Holdings Co., Ltd.

The Otsuka Group is a diversified healthcare group operating globally under the corporate philosophy ‘‘Otsuka-people creating new products for better health worldwide''. The Otsuka Group has business operations in 23 countries and regions around the world, and its consolidated sales for fiscal 2010 is ¥1,090.2 billion. For more information, please visit the company's website at www.otsuka.com/en/.

SPANIDIN®

Alizée — 2010-12-20T13:39:21Z

The Nordic Pharma Group announces a strategic collaboration with Nippon Kayaku on Spanidin(r) (gusperimus) in selected territories outside Japan, including Europe.

Tokyo, Japan and Paris, France (December 20, 2010). Nippon Kayaku (NK) and the Nordic Pharma Group (Nordic) have signed a licensing agreement under which NK grants exclusive rights to NORDIC for the development and commercialisation of Spanidin(r) (gusperimus) in selected territories outside of Japan, including Europe.

Spanidin(r) is an immunosuppressive agent developed and commercialised in Japan by NK in acute and accelerated rejection crisis after renal transplantation. The product has also obtained promising results and orphan medicinal product status in Europe for the treatment of Wegener´s Granulomatosis (WG).

Under this agreement, Nordic will design and execute the global clinical development of Spanidin(r), which includes a pivotal, comparative Phase III study for patients suffering from WG relapse. Nordic will also be responsible for the regulatory filing and commercialisation of the product in the relevant countries. NK will ensure production of the active ingredient until registration and beyond.

Spanidin(r) has the potential to offer a treatment for relapsing WG patients, who currently have no approved drug to cure their disease.

With this new agreement, Nordic is actively pursuing its strategy to bring innovative drugs to the market in specialized therapeutic areas that have specific, unmet medical needs.

About Wegener’s Granulomatosis
Wegener’s Granulomatosis is a form of primary, systemic vasculitis with granulomatous inflammation of the respiratory tract combined with necrotising vasculitis of the small to medium sized blood vessels. Although it primarily involves the respiratory tract, lungs and kidneys, almost any organ can be affected. WG is a rare disease with an estimated prevalence of 42 to 63 per million inhabitants in the European Union. In the past, prognosis was poor, with a mortality rate of 80% within a year.
The development by Fauci and co-workers in 1983 of a treatment regimen using cyclophosphamide (CYC) and prednisone improved the prognosis, and the disease became one marked by remissions and relapses (i.e., recurrence or new onset of disease activity represented by active inflammation) associated with significant morbidity. Improvement or remission can be achieved in 75% to 90% of patients. However, WG remains life threatening with frequent relapses, and treatment, which in itself is associated with high morbidity and mortality, is needed on a long-term basis.
To induce remission in naive patients, the first treatment of choice is oral CYC in combination with corticosteroids. CYC is associated with an increased risk of bladder cancer. The estimated incidence of bladder cancer was 16% after 15 years, and the risk is proportional to the cumulative CYC dose. CYC can cause gonadal toxicity and reproductive failure, is known to be hepatotoxic, and can cause bone marrow toxicity.
Approximately 10 % of patients do not respond to CYC and corticosteroids. Furthermore, some patients cannot tolerate the treatment or continue to relapse.

About Spanidin(r)
Spanidin(r) (gusperimus) is a chemically synthesised immunosuppressant, which was developed in collaboration with Institute of Microbial Chemistry and Takara Shuzo. It suppresses the functions of various immunocompetent cells, i.e., T-lymphocytes, B-lymphocytes, macrophages and dendritic cells. Through its specific binding to Hsp70, a heat shock protein, it inhibits the chaperone function of Hsp70 family proteins, the translocation of NF-κB to the nucleus and the loading of antigenic peptides into MHC molecules. It also inhibits the activation of dendritic cells by Hsp70. This mechanism is unique to gusperimus and different from presently used immunosuppressive agents, such as calcineurin inhibitors (cyclosporin and tacrolimus), mammalian TOR (sirolimus) and anti-metabolites (mycophenolate mofetil).
Gusperimus is effective as a single prophylactic and therapeutic agent in prolonging allograft survival in mice, rats, dogs, and non-human primates. Furthermore, combining gusperimus with other immunosuppressants, such as steroids, cyclosporin and tacrolimus, is useful for prolonging allograft survival rates.
Gusperimus is also effective in various autoimmune animal models, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, crescentic glomerulonephritis, Type I diabetes, uveitis, idiopathic thrombocytopenia purpura, and colitis.
An early phase II study was performed in Germany from 1999 to 2000 on 20 patients with intractable ANCA-associated vasculitis (19 Wegener’s Granulomatosis patients and 1 microscopic polyangiitis patient). Gusperimus was intravenously (only in the first week of the first course) or subcutaneously administered once a day at 0.5 mg/kg/day for 28 days. If the White Blood Cell (WBC) count dropped to 3000/μl during the period, administration was suspended until a least a WBC of 4000/μl was reached again. This was repeated for up to 6 cycles. During the study, no other immunosuppressants, except steroids, were allowed. Improvement during treatment was achieved in 70% of the cases. Most of the patients experienced transient leucopoenia of a similar pattern (decrease after administration and recovery before next course) during the study. No mortality or septicaemia was observed. Mild to moderate infections, mainly of the respiratory tract, were observed but resolved under appropriate treatment without after-effects.
A late Phase II study was performed in Europe from 2003 to 2006 on 45 patients with refractory Wegener’s Granulomatosis. Gusperimus was self-administered subcutaneously at 0.5 mg/kg/day for 21 days followed by a minimum, seven-day rest period. Each patient was supposed to receive six treatment cycles. The response rate as per the study protocol definition was 92%, with complete remission in 46% patients and partial remission in 46% patients. The most clinically significant side effects were reversible leucopoenia, neutropoenia and anaemia. All side effects were manageable and reversible.

Mitomycin C

Laura Wild Berthier — 2010-05-01T12:58:00Z

The Nordic Group obtains the marketing rights for Mitomycin C Kyowa in Central & Eastern Europe.

The Nordic Group obtained on May 1st, 2010, the exclusive marketing rights for Mitomycin C, an antineoplastic agent from Kyowa Hakko Kirin Co. Ltd. in the Czech Republic, the Slovak Republic, Hungary, Poland, and Bulgaria, as well as Russia, the Ukraine and Georgia.

Mitomycin C Kyowa was launched in Central & Eastern European countries about 25 years ago and until now, it has been commercialized through different distributor channels.

Mitomycin C Kyowa is prescribed in the treatment of malignant neoplastic diseases, including disseminated adenocarcinoma of the stomach, pancreas and colon. However, its main use is as an instillation after resection in the treatment of non-muscle invasive bladder cancer.

The Nordic Group is a pan European, fully integrated pharmaceutical company focused on hospital products in a few, selected therapeutic areas that have significant unmet medical needs.

Nordic Pharma Italy

Laura Wild Berthier — 2010-03-01T13:38:00Z

After its creation in 2009, Nordic Pharma S.r.l. launched its new offices in Milano on March 1st, 2010.

The Nordic Group's Italy affiliate is now fully operational and prepared for further growth in the field of gynaecology and hospital therapeutic areas.

Management Team

inouit — 2009-05-12T09:27:31Z

Drs. Hans Schram - CEO and Managing Director

Drs. Schram has a Chemistry degree from Leiden University in the Netherlands and over twenty years of experience in the global Pharmaceutical industry.
Prior to joining Nordic, he spent 18 years at Ferring, where he was a member of the Executive Management team.
Prior to Ferring, he was at Ciba Geigy and at Pierre Fabre Laboratories.
Drs. Schram joined the Nordic Group as the CEO and Managing Director in 2002.

The Nordic Group
216, boulevard St. Germain
75007 Paris
France
Tel. +33 1 53 63 88 77
Fax +33 1 45 48 76 50
info@nordicpharma.com

Stéphane Altaba, PhD, Director Corporate Business Development

Dr. Altaba has an engineering degree in Agronomy, a PhD in Biotechnology and a postgraduate degree in Management from the ESCP-EAP business school. For over 10 years, he had responsibilities in R&D and Industrial Affairs in RPR, and in Business Development within Aventis and Sanofi Aventis. In his last assignment at Sanofi Aventis, he was in charge of Corporate Business Development for the Oncology franchise. Dr. Altaba joined the Nordic Group in August 2006.

The Nordic Group
216, boulevard St. Germain
75007 Paris
France
Tel. +33 1 53 63 88 77
Fax +33 1 45 48 76 50
info@nordicpharma.com

Charlotte Phelps, General Manager of Nordic Pharma UK

After an early career in research, Ms. Phelps moved to the Pharmaceutical industry in mid-80’s. Following a successful time in sales, she moved to Global Marketing, where she was responsible for a number of product ranges including the launch of a new chemical entity in Obstetrics. Ms. Phelps has experience in a wide range of therapy areas, including Cardiovascular, Mental health, Endocrinology, Critical Care, Haematology and Obstetrics.
Ms. Phelps is responsible for establishing and running the Nordic UK affiliate as of mid-2002.

Nordic Pharma UK
Abbey House
1650 Arlington Business Park
Theale, Reading RG7 4SA
United Kingdom
+44 118 929 8233
+44 118 929 8234
info@nordicpharma.co.uk

Dr. Véronique Rebours-Mory, General Manager of Nordic Pharma FR

Dr Rebours-Mory is a Pharmaceutical doctor from the University of Lyon. She started her career in the late 80’s and has since developed her skills in Sales, Marketing, Operational Clinical Development, European Project Management, International Business Development, and General Management in fully integrated Pharmaceutical companies. She also has experience in several therapeutic areas, including Neurology, Infectious Diseases, Oncology, Gynaecology, Gastroenterology, Critical Care and Rheumatology. Dr. Rebours-Mory joined the Nordic Group in 2002 to create and develop Nordic’s French affiliate.

Nordic Pharma France
10, rue René Anjolvy
94250 Gentilly
France
Tel. +33 1 72 46 72 00
Fax +33 1 72 46 72 29
info@nordicpharma.com

Günter Lützenkirchen, General Manager of Nordic DE

Dr. Lützenkirchen has a background in Chemistry and Biology with a Ph.D. in Biology from the University of Freiburg/Brsg.
He started his marketing-based career as a Product Manager with Ciba-Geigy and Sandoz. He then held various positions of increasing responsibility in Marketing and General Management with Pharmacia and Searle, Antisense Pharma, and Brand Institute Germany. His most recent position in the pharmaceutical industry was as Managing Director of the German affiliate of Biogen Idec GmbH.
Dr. Lützenkirchen joined Nordic Group on July 1^st, 2008 as the General Manager of Nordic’s German affiliate.

Nordic Pharma Germany
Fraunhoferstr.4
85737 Ismaning
Germany
Tel. +49 89 889 690 680
info@nordicpharma.de

Ivana Stivinova, M.D, General Manager of Nordic Pharma CZ

Dr. Stivinova graduated as a medical doctor. She began working in the pharmaceutical industry over 15 years ago, when she joined Glaxo as sales representative.
Dr. Stivinova then spent nearly 10 years in Ferring both as a Product Manager and as a Marketing & Sales Manager in the Czech Republic. She eventually became an International Project Specialist in Ferring in Copenhagen and later the Marketing & Sales Manager for Central and Eastern Europe (based in Vienna).
Dr. Stivinova joined the Nordic Group in 2003 to manage the challenging job of General Manager, Nordic Pharma Czech Republic, as well as to oversee all Marketing and Sales activities there and in the rest of Central and Eastern Europe.

Nordic Pharma Czech Republic
Zachova
140 000 Prague 4 - Krc
Czech Republic
Tel. +420 241 029 544
info@nordicpharma.cz

Anders Löfgren, DDS, MBA, Managing Director of Nordic Drugs

Mr. Löfgren has a double qualification as a DDS (Doctor of Dental Surgery) and as an MBA. Mr. Löfgren is also a trained Army Officer with the rank of Captain.
Mr. Löfgren counts an impressive 18 years in the Pharmaceutical Industry in various well-known companies (Ciba-Geigy, Searle, Ferring). He has broad Marketing experience both in Scandinavia and in the rest of Europe.
Mr. Löfgren was one of the first to join the Nordic Group of companies, back in 1996.

Nordic Drugs Sweden
Geijersgatan 2 A
200 61 Limhamm
Sweden
Tel. +46 40 36 66 00
info@nordicdrugs.se

Paul Rohof, M.D., General Manager of Disphar

Disphar International
Tolweg 15
3741 LM Baarn
The Netherlands
Tel. +31 35 5280 403
Fax. +31 35 5480 585

Kenneth Stokholm, Managing Director of QPharma

Mr. Stokholm has a technical background in chemical engineering and holds an MSc. He joined the pharmaceutical industry in Novo Nordisk in Denmark and has since held various leading positions within Supply Chain and Operations as well as Project Management.
His last assignment was establishing a pharmaceutical facility for Alpharma in Taizhou, China, where he held the position as Managing Director. The facility was built, the organisation established and developed and the site is today in operation and approved by FDA.
Mr. Stokholm joined QPharma, and the Nordic Group, in January 2009.

QPharma
Agneslundsvägen 27
20 125 Malmö
Sweden
Tel. +46 40 36 18 00
Fax +46 40 18 28 55
info@qpharma.se

Petr Janda, MD, General Manager of Prague Clinical Services

Dr. Petr Janda is a medical doctor who graduated with specialisations in Internal Medicine and Nephrology from Charles Univesity in Prague, Czech Republic. He has over 16 years of experience in clinical studies, in particular within Ciba Geigy and Ferring. In the past, he was responsible for worldwide clinical activities from phase I – IV, as well as registration and pharmacovigilance activities.
Dr. Janda has been Managing Director of Prague Clinical Services since 2004 and under his guidance Prague Clinical Services has grown into one of the most prominent independent CROs in Central & Eastern Europe. Moreover, Dr. Janda is the President of ACRO-CZ (the Czech CRO Association) and a management team member of EUCROF (the European CRO Federation).

Prague Clinical Services
Zachova 8
140 00 Prague 4 – Krc
Czech Republic
Tel. +420 241 029 551
Fax. + 420 241 442 852
info@pragclin.com

Nordic Pharma Germany

Laura Wild Berthier — 2009-01-03T15:07:00Z

The Nordic Group's German affiliate is now fully operational.

After its creation in 2008, Nordic Pharma GmbH announced the launch of its new offices in the Ismaning business park near Munich on January 1st, 2009.
The Nordic Group's German affiliate is now fully operational and prepared for further growth as a preferred partner in the speciality and hospital therapeutic areas.
Nordic Pharma Germany currently markets three innovative hospital products : Synercid(r), Siklos(r) and Hyalobarrier(r).

Contact Us

inouit — 2008-04-28T09:43:37Z

Corporate/Business Development
216 Boulevard St. Germain 75007 Paris France Tel. +33 1 53 63 88 77 Fax. +33 1 45 48 76 50 info@nordicpharma.com business.development@nordicpharma.com

Nordic Drugs

Nordic Drugs - Sweden

Nordic Drugs - Denmark

PO Box 30035

Geijersgatan 2 A
S-200 61 Limhamm
Sweden
Tel. +46 40 36 66 00

Fax. +46 40 36 66 01
info@nordicdrugs.se

GI. Kongevej 135 B mezz., tv.,

DK-1850 Frederiksberg C

Denmark
Tel. +45 70 20 08 40

Fax. +45 70 20 08 42

info@nordicdrugs.dk

Nordic Drugs - Norway

Nordic Drugs - Finland

PO Box 47

Vinderen,
N-0319 Oslo
Norway
Tel. +47 23 22 11 44

Fax. +47 33 30 84 31

info@nordicdrugs.no

PO Box 800

World Trade Center

Aleksanterinkatu 17

SF-00101 Helsinki
Finland
Tel. +358 10 231 1040

Fax. +358 10 231 1041

info@nordicdrugs.fi

Nordic Pharma

Nordic Pharma - UK	Nordic Pharma - France
Abbey House 1650 Arlington Business Park Theale, Reading RG7 4SA United Kingdom Tel +44 118 929 8233 info@nordicpharma.co.uk	254, Bd Saint Germain 75007 Paris France Tel. +33 1 70 37 28 00 info@nordicpharma.com

Nordic Pharma - Czech Republic

Nordic Pharma - The Netherlands

Nad Svahem 1766/6
140 000 Praha 4
Czech Republic

Tel +420 241 080 770
info@nordicpharma.cz

Tolweg 15
3741 LM Baarn
The Netherlands

Tel. +31 35 5480 580
Fax : +31 35 5480 589
info@nordicpharma.nl

Nordic Pharma - Belgium	Nordic Pharma - Poland
Garden Square A Laarstraat 16 2610 Wilrijk Belgium Tel. +32 3 820 52 24 info@nordicpharma.be	ul. Raclawicka 133 m.9 02-117 Warszawa Poland Tel/Fax. +48 601 991 119 info@nordicpharma.cz

Nordic Pharma - Germany

Nordic Pharma - Italy

Fraunhoferstr.4
85737 Ismaning
Germany

Tel. +49 89 889 690 680
E-mail. info@nordicpharma.de

Via Venezia 23
20099 Sesto San Giovanni (MI)
Italy

Tel. +39 02 241 26710/26711
Fax : +39 02 241 26712
E-mail. info@nordicpharma.it

Pharmaceutical Services

Prague Clinical Services - Czech Republic	QPharma - Sweden
Zachova 8 140 00 Praha 4 The Czech Republic Tel. +420 241 029 551 Fax. + 420 241 442 852 info@pragclin.com	Agneslundsvägen 27 201 25 Malmö Sweden Tel. +46 40 36 18 00 Fax. + 46 40 18 28 55 info@qpharma.se

Disphar International - The Netherlands

Tolweg 15
3741 LM Baarn
The Netherlands
Tel. +31 35 5280 400
Fax. +31 35 5480 585

info@disphar.com

Hyalobarrier®

Alizée — 2008-01-22T13:34:00Z

On January 22, 2008, the Nordic Group was granted the exclusive marketing and distribution rights to Hyalobarrier(r) for a number of European countries by Fidia Advanced Biopolymers.

Hyalobarrier(r) gel is the highly advanced bio-technology specialty product used for the prevention of post-surgical adhesions in abdominopelvic surgery.

Adhesions are internal scars : strand-like fibrous tissue that forms abnormal bonds between two parts of the body. After abdominal or pelvic surgery, adhesions can lead to severe clinical complications, such as bowel obstruction, infertility, and chronic abdominal or pelvic pain. There is a significant unmet medical need for the prevention of adhesions and their potential complications.

Hyalobarrier(r) is composed of an aqueous gel of ACP200(r), an original auto-cross-linked ester of hyaluronic acid, and the product is an highly effective barrier for protecting and separating tissues after abdominopelvic surgery. Given its physical characteristics, Hyalobarrier(r) perfectly adheres to the tissue surface and to the abdominal wall, and is easy to manipulate during laparotomic, laparoscopic and hysteroscopic procedures. The product completely degrades within 7 days by following the natural pathway of hyaluronic acid

The Nordic Group will commercialize Hyalobarrier(r) in France, United Kingdom, Ireland, the Benelux, Denmark, Sweden, Norway, Finland, Iceland, Czech & Slovak Republics, Poland, Bulgaria and in Germany, and intends to launch the product in the second half of 2008.

Indeus Life Sciences

inouit — 2007-11-12T18:24:16Z

INDEUS Life Sciences is a recently-established, Mumbay-based pharmaceutical development laboratory providing complete and high-quality formulation development services in full compliance with international standards and regulations, and in particular with those in the EU and the USA. The company’s services include the following :

Formulation development
Process validation
Analytical method development and validation
Technology transfer services
Stability studies as per ICH guidelines

The experienced management of INDEUS has extensive knowledge in product development for the US and EU markets.

INDEUS Life Sciences
SU Motor's Complex
Balrajeshwar Road
Model Town, Mulund (W),

Mumbai
Maharashtra 400 080, INDIA
Tel. +91-22-4161-1123
Fax. +91-22-2591-6792
Email. indeus@indeus.in